Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Oxford Lane Capital Corp — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.02 (market cap $12.58B), while Oxford Lane Capital Corp trades at $8.66 (market cap $835.71M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 15.1× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Oxford Lane Capital Corp for 49 Days on average.
| HALO | OXLC | |
|---|---|---|
Market Cap | $12.58B | $835.71M |
Volume | 2,179,278 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $115.22 | $16.74 |
52-Week Low | $61.63 | $8.15 |
Typical Hold Time | 1 Days | 49 Days |
Enterprise Value | $14.49B | $1.23B |
Dividend Yield | — | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OXLC trades at $8.535, up 0.89% on the day, with a bearish technical signal from moving averages. The stock shows a low P/B of 0.81 and a high net income margin of 100.85% for 2025, but recent earnings misses and a sharp decline in 2026 revenue and net profit to negative figures highlight significant volatility. The company maintains a regular dividend payout of $0.20 monthly, supported by financing activities, but faces challenges from operational cash outflows and negative ROE/ROA.
Outlook is cautious due to earnings instability and bearish technicals, though the dividend yield may attract income seekers. Key risks include sustained operational losses, high interest expenses, and reliance on financing for dividends. Analyst consensus is mixed with 50% buy ratings, indicating divided sentiment on recovery potential amid current headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
